中药复方肠吉泰治疗腹泻型肠易激综合征的临床随机对照观察

Randomized Controlled Clinical Study on Effect of Chinese Compound Changjitai in Treating Diarrheic Irrita- ble Bowel Syndrome

目的:验证中药复方肠吉泰(简称肠吉泰)治疗腹泻型肠易激综合征的临床疗效及安全性。方法:采用非盲法随机对照设计,将45例患者随机分为两组,并分别用肠吉泰(治疗组30例)和得舒特(对照组15例)治疗,采用症状尺度表、大便性状表记录两组患者主要症状变化,并记录与药物相关的不良反应。结果:总有效率治疗组为83.3％,对照组为73.3％。肠吉泰在改善患者大便性状、减少腹泻患者排便次数、减少排便急迫感天数方面,其疗效均优于得舒特(P<0.05),同时未见与药物有关的不良反应。结论:肠吉泰治疗腹泻型肠易激综合征疗效肯定,且无毒副反应。

Objective: To verify the clinical efficacy and safety of the proven Chinese Compound Changjitai (CJT), in treating the diarrheic irritable bowel syndrome (DIBS). Methods: Randomized controlled open clinical trial design was adopted, 45 patients were randomly divided into two groups, CJT and pinaverium bromide (PVB) were given as treated and control agent respectively. IBS scoring system (BSS), defecation state questionnaire (DSQ) were used to record the changes of the patients main symptoms before and after treatment. Results: The total effective rate of CJT group was 83.3 %, while that of PVB was 73.3 % . CJT was superior in efficacy to that of PVB in improving stool quality, reducing defecation episodes of diarrheic patients, alleviating tenesmus symptoms, decreasing bellyache days and ameliorating abdominal distention. Any drug-related adverse reaction was not seen. Conclusion: The efficacy of CJT in treating DIBS is definite and without any toxic and adverse effects.